Resources

A total of 215 deals were announced in the Asia-Pacific (APAC) region during the week ended 29 March 2020, according to GlobalData’s deals database. The number marked a decrease of 18.6% when compared with 264 deals announced during the previous week. Deal...

A total of 837 deals were announced globally during the week ended 29 March 2020, according to GlobalData’s deals database. The number marked a decrease of 19.7% when compared with the 1,042 deals announced during the previous week. The subdued activity, which...

QIAGEN has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its QIAstat-Dx Respiratory SARS-CoV-2 Panel test to diagnose patients infected with coronavirus (Covid-19). The newly developed test kit is the first and only...

South Africa’s president Cyril Ramaphosa announced on Monday that the country will embark on a mass COVID-19 screening programme. He announced that 10,000 workers would be visiting citizens’ homes in order to carry out screenings for coronavirus symptoms....

According to cybersecurity firm Proofpoint, 80% of scams, hacks and cyberattacks are now coronavirus-themed. Since the security firm began monitoring for coronavirus scams on 29 January, it has observed over 500,000 messages, 300,000 malicious URLs and 200,000...

If CEOs have empowered their teams effectively, they have three roles during times of rapid change: Motivator in chief (Championing culture & values, ensuring the team stays true to these) Focuser in chief (Setting strategy and ensuring that stakeholders align...

Back in 2012, Aveo announced that its second most advanced asset, ficlatuzumab, had flopped in a midstage cancer test; for years, we heard nothing about this drug.

Mining the blood of recovered patients for treatments during a pandemic isn’t a new idea. Takeda and Grifols are already doing it, working on antibody-rich drugs made from the plasma of patients who have fought off COVID-19 infection. GigaGen thinks its approach...

The former Fierce 15 winner delivered new cardiac biomarker data showing its late-phase mavacamten compound can help improve signs of heart stress and injury in hypertrophic cardiomyopathy.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years—as well as in cases of heart attack or stroke—between people that had received a drug-eluting stent for...

Medtronic is back with new data finally demonstrating the effectiveness of its catheter-based ablation procedure aimed at the kidneys to help lower high blood pressure where multiple medications have failed.

For Bruce Booth, partner at Cambridge, Mass.-based Atlas Venture, data are the “ultimate currency of progress and market value” for the biotech startups that he creates and funds. Read more. The post Biotech in the time of the coronavirus: With China...

In the throes of a full COVID-19 pandemic, most business leaders’ top priority is rightfully the health and safety of their employees, families, and communities. Even though business disruptions are significant and overwhelming, the primary efforts focused on...

I have never participated in trench warfare and I am sure it was pretty grim for those who lived and suffered through it. I have spent plenty of time however ‘in the trenches’ in biotech. Just like the stories of war, I have made it through the tough times...

His idea to reprocess used medical devices is already helping reduce waste in the New Zealand healthcare sector. Now Oliver Hunt of Medsalv discusses plans for the future and what’s needed for a small business to hum. In healthcare, the need for sanitation and...

Like many middle-aged weekend warriors, I’ve been recently sidelined by injury simply through doing what I’ve regularly done: run. Injury stopped me from running last fall and I’ve since seen orthopods and running experts galore. But it’s been...

M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups. Read more. The post BioPharma M&A Drives More Efficient Resource Allocation appeared first on Atlas Venture.

As it gears up to move its immuno-oncology programs into the clinic, Akrevia Therapeutics has reeled in a $100.5 million series B and changed its name to Xilio Therapeutics to mark its transition from a research-focused company to an R&D-stage one. Read...

The post Winter 2020 Newsletter appeared first on AMDR.

Americans spend more on healthcare than anyone else in the world. Although the high cost of prescription drugs are often thought of as a primary driver – and make no mistake, Americans spend double the cost for the same drugs paid by patients of 10 other...

Thanks to Health Care Without Harm, EU-based hospitals and national health systems have a new roadmap to strategic procurement.  The Association of Medical Device Reprocessors, or AMDR, hopes EU hospital leadership will spend time reviewing Health Care...

My first job at a public company was when I joined Biogen or Biogen Idec as it was then called. One of the rituals of the team was to listen in to the quarterly earnings calls, usually on speaker in a conference room as we drank our morning cup of joe and caught up...

Grand View Research, Inc. estimates that the global reprocessed medical devices market is expected to reach USD 5.0 billion by 2022. Increased generation of medical waste and the “long-term cost efficiency associated with these devices” are addressed as...

Biotech is in the midst of an incredible era of innovation: new modalities and novel medicines delivering real value to patients, leading to a decade-long bull cycle. It’s been exhilarating to watch and participate in this market, and venture capital activity in...

Cells die all the time in a controlled manner that’s perfectly normal. But the way cells die matters. Sometimes cell death is violent, sparking inflammation believed to contribute to disease. Quench Bio aims to develop drugs that stop the uncontrolled forms of...